Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial

Static biomarkers like programmed death-ligand 1 (PD-L1) are insufficient to accurately predict response to immune checkpoint inhibition. Therefore, on-treatment biomarkers, which measure immediate therapy-associated changes, are currently shifting into the focus of immuno-oncology. A prime example...

Descripción completa

Detalles Bibliográficos
Autores principales: Saal, Jonas, Bald, Tobias, Eckstein, Markus, Ritter, Manuel, Brossart, Peter, Ellinger, Jörg, Hölzel, Michael, Klümper, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121335/
https://www.ncbi.nlm.nih.gov/pubmed/37004206
http://dx.doi.org/10.1093/jncics/pkad027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121335/
https://www.ncbi.nlm.nih.gov/pubmed/37004206
http://dx.doi.org/10.1093/jncics/pkad027

Ejemplares similares